RIGL250117P17000
- 1.31
- 0.000.00%
Rigel Pharmaceuticals Newsroom
Rigel Pharmaceuticals Shares Are Trading Lower After B. Riley Securities Cut Its Price Target on the Stock From $27 to $20.
Express News | Rigel Pharmaceuticals Shares Are Trading Lower After B. Riley Securities Cut Its Price Target on the Stock From $27 to $20
Rigel Pharmaceuticals Price Target Raised to $25 From $15 at Cantor Fitzgerald
Rigel Pharmaceuticals Price Target Raised to $25.00/Share From $15.00 by Cantor Fitzgerald
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 40% Undervaluation?
Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data From Cancer Drug Study
Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...
B.Riley Financial Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $27
B. Riley Adjusts Price Target on Rigel Pharmaceuticals to $27 From $17, Maintains Neutral Rating
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Rigel Pharmaceuticals Says Its R289 Hematology Drug Candidate Receives Fast-Track Designation From US FDA
Express News | Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
How Much Upside Is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
Rigel Pharmaceuticals Price Target Raised to $23 From $15 at Piper Sandler
Rigel Pharmaceuticals Analyst Ratings
Rigel to Present at the Jefferies London Healthcare Conference
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $49
Citi Sees Good Things Ahead for Rigel -- Market Talk